Trial Profile
The feasibility study and biomarker research of afatinib in patients with previously treated advanced NSCLC harboring EGFR mutation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2014
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Nov 2014 New trial record